The Endocannabinoid System May Modulate Sleep Disorders in Aging

Eric Murillo-Rodriguez1,2,*, Henning Budde2,3, André Barciela Veras2,4, Nuno Barbosa Rocha2,5, Diogo Telles-Correira2,6, Diogo Monteiro2,7,8, Luis Cid2,7,8, Tetsuya Yamamoto2,9, Sérgio Machado2,10 and Pablo Torterolo2,11

1Laboratorio de Neurociencias Moleculares e Integrativas, Escuela de Medicina, División Ciencias de la Salud, Universidad Anáhuac Mayab, Mérida, Yucatán, México; 2Intercontinental Neuroscience Research Group; 3Faculty of Human Sciences, Medical School Hamburg, Hamburg, Germany; 4Dom Bosco Catholic University, Campo Grande, Mato Grosso do Sul, Brazil; 5School of Health, Polytechnic Institute of Porto, Porto, Portugal; 6University of Lisbon, Faculty of Medicine, Lisbon, Portugal; 7Sport Science School of Rio Maior-Polytechnic Institute of Santarém, Rio Maior, Portugal; 8Research Center in Sport, Health and Human Development-CIDESD, Vila Real, Portugal; 9Graduate School of Technology, Industrial and Social Sciences, Tokushima University, Tokushima, Japan; 10Laboratory of Physical Activity Neuroscience, Physical Activity Sciences Postgraduate Program, Salgado de Oliveira University, Niterói, Brazil; 11Laboratorio de Neurobiología del Sueño, Departamento de Fisiología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay

Abstract: Aging is an inevitable process that involves changes across life in multiple neurochemical, neuroanatomical, hormonal systems, and many others. In addition, these biological modifications lead to an increase in age-related sickness such as cardiovascular diseases, osteoporosis, neurodegenerative disorders, and sleep disturbances, among others that affect activities of daily life. Demographic projections have demonstrated that aging will increase its worldwide rate in the coming years. The research on chronic diseases of the elderly is important to gain insights into this growing global burden. Novel therapeutic approaches aimed for treatment of age-related pathologies have included the endocannabinoid system as an effective tool since this biological system shows beneficial effects in preclinical models. However, and despite these advances, little has been addressed in the arena of the endocannabinoid system as an option for treating sleep disorders in aging since experimental evidence suggests that some elements of the endocannabinoid system modulate the sleep-wake cycle. This article addresses this less-studied field, focusing on the likely perspective of the implication of the endocannabinoid system in the regulation of sleep problems reported in the aged. We conclude that beneficial effects regarding the putative efficacy of the endocannabinoid system as therapeutic tools in aging is either inconclusive or still missing.

Keywords: Cannabidiol, childhood, pharmacology, sleep, rapid eye movement sleep, Aging.

1. INTRODUCTION

The demographic and epidemiologic projections have indicated growth in longevity worldwide in the coming years [1-3]. A critical distinction is between 1900, when only 4.1% of the 76 million people in the United States were ≥65 years old, 1950 with 8% of the total population under the same age, and 2000 with a percentage that had increased to 12.6% [4]. These numbers are enhancing worldwide since fertility and mortality rates are declining in most countries [5, 6]. Aging is also linked with the coexistence of two or more chronic medical conditions, known as multimorbidity [7-9] leading to interactions between multiple disorders as well as among treatments prescribed for different disorders [9-12]. The geriatric-related health issues comprise multiple medical conditions such as hypertension, stroke, sleep disorders, among others [6, 13-18].

2. SLEEP MEDICINE AND AGING

The sleep-wake cycle is a complex biological phenomenon that involves the interaction of multiple complex neurobiological networks, including neuroanatomical, neurochemical, and genetic factors [19-24]. Normal sleep comprises two states, Non-REM (NREM) sleep, that has three phases (N1 to N3), and Rapid Eye Movement sleep (REMS). However, during aging, sleep displays aberrant features [25-29]. The sleep disorders have been classified by the Ameri-
can Academy of Sleep Medicine into the “International Classification of Sleep Disorders -third edition” (ICSD-3). Amongst the most common sleep complaints in the aged population are insomnia and excessive daytime sleepiness (EDS) or hypersomnolence [30-37].

Insomnia has been classified in several subtypes by polysonomographic studies and additional criteria. Sleep onset insomnia (persistent difficulty in sleep initiation), sleep maintenance insomnia (difficulty to maintain sleep during nighttime), early morning insomnia (identified with early morning awakenings), and psychophysiological insomnia (cognitive and behavioral elements, stress, intrusive thoughts, and attention bias) are reported in aging.

Based on the duration, insomnia is categorized in transient (few insomniac episodes before or during a stressful experience), short-term (events presented along a few weeks during an extended period of stress), or chronic (sleep disturbance and associated daytime symptoms have been present for at least three months) [30, 31, 36]. Remarkably, chronic insomnia affects 57% of the elderly in the USA [37-39].

On the other side of the coin, EDS is understood as the irresistible tendency to fall asleep during daytime [25, 27, 34, 40]. The diverse causes that originate EDS include, for instance, obstructive sleep apnea (interruptions in breathing during sleep for > 10 s leading to intermittent, partial, hypopnea, and/or complete (apnea) collapse of the upper airway during nighttime). Because of obstruction, any inspiratory effort causes snoring. In turn, this issue is commonly associated with the awakening of the subject across nighttime leading to sleep fragmentation. On the next day, and as a consequence, sleep fragmentation produces EDS [41-43], which is very common in older adults [44-47].

An additional sleep disturbance in aging is the periodic limb movement disorder (PLMD), characterized by repetitive cramping or jerking of the legs during sleep. PLMD is another cause of EDS [46-50]. Patients complaining of PLMD show involuntary and stereotypical movements of their limbs while they sleep. The movement of limbs across night induces recurrent awakenings that limit sleep consolidation and eventually, causes drowsiness on the next day. The prevalence of PLMD is higher among older adults [51-53].

Lastly, the neurodegeneration of a cluster of neurons located in the lateral hypothalamus, named orexin or hypocretin, seems to be the origin of the sleep disturbance named narcolepsy [54]. The core symptoms of this disease comprise extreme sleepiness (sleep attacks) during daytime and cataplexy [28, 54-56]. Although narcolepsy has been normally found during the adolescence, recent data have suggested the putative link between hypocretin/orexin and aging [57-61].

Currently, most of the sleep disturbances reported in aged subjects are managed by pharmacological interventions. Medical prescriptions for the elderly include antidepressants, antihistamines, sedative-hypnotics, among others [41, 49, 51, 53, 54, 62, 63]. However, since the study of the properties of the endocannabinoid system in modulating wider spectrum of neurobiological phenomena, we would like to highlight the putative use of the endocannabinoid system elements in sleep disorders during aging.

3. THE ENDOCANNABINOID SYSTEM

During the 1990s, several experimental approaches were designed to describe the transmembranal proteins that pharmacologically responded to the principal compound of Cannabis sativa, the delta-9-tetrahydrocannabinol (Δ9-THC). At this date, it is widely accepted that the receptors that respond to Δ9-THC are CB1 and CB2 cannabinoid receptors [64-67]. In addition, the presence of both receptors has been mapped in different organs, including the human brain [68-71].

Next, the quest of the endogenous ligands that naturally bind to these receptors leads to the discovery of the first agonist to the cannabinoid receptors named arachidonylethanolamine or anandamide, and in later years, the second lipid with cannabimimetic properties was described: 2-arachidonylglycerol (2-AG) [72]. Currently, the family of the endocannabinoids comprises different compounds aside anandamide and 2-AG, such as virdohamide, noladin ether, and N-arachidonylidopamine [73-77]. In addition, the endocannabinoid system is integrated by several molecular elements, including the enzymes that synthesize/degrade anandamide (fatty acid hydrolase [FAAH]) or 2-AG (monocaylglcerol lipase [MAGL]), the anandamide membrane transporter (AMT) and the receptor channel TRPV1 (Transient Receptor Potential Vanilloid 1; [78-82]). Along the decades, preclinical studies have shown that the endocannabinoid system exerts critical neurobiological functions, some of them, with clinical relevance, including the control of the sleep-wake cycle [80, 83-93].

4. THE ENDOCANNABINOID SYSTEM IN HEALTH ISSUES

Multiple experimental models strongly suggest that the endocannabinoid system plays a critical role in numerous pathologies. Converging preclinical experiments, including a wider spectrum of data, from modulating the endogenous tone of anandamide, to the treatment with a direct CB1 cannabinoid receptor agonist/antagonist, the pharmacological inhibition of the FAAH, or the genetic deletion of cannabinoid receptors, have been shown to control adverse medical conditions, such as schizophrenia, and ataxias. Amongst these pathological issues, important advances have been achieved in neurodegenerative disorders, including Parkinson’s and Alzheimer disease [94-101]. Yet the hypothesis that the endocannabinoid system might be critically involved in ongoing pathologies associated with aging, such as sleep disorders, has been dismissed. However, an accumulating body of evidence is providing pieces to the puzzle to appreciate the putative role of the endocannabinoid system in the modulation of sleep disorders in the elderly.

5. AGING AND THE ENDOCANNABINOID SYSTEM

It is often argued that aging is associated with multiple deteriorating medical conditions, such as neurodegenerative disorders, leading to the dysregulation of endogenous neurochemical compounds. In this regard, the levels of anan-
transmission
of URB597, OEA or PEA, including the dopaminergic ne
SWS and REM sleep mimicking URB597’s effects

expression has been found higher compared to age-matched controls [104-106]. Furthermore, the lack of the CB2 cannabino
d receptors has been linked with schizophrenia-like pathologies whereas contents of anandamide are signifi-
cantly enhanced in schizophrenic patients compared to re
pective controls [107-110]. Taken together, these data obli-
gate us to address an important question that remains to be
answered: Are the health disturbances the cause or conse-
quency of the disruption of the endocannabinoid system
functioning? While pertinent experimental approaches are
aimed to address this concern, the body of evidence sug-
states that there is a neurobiological role of the endocannabi-
noid system in aging processes, including perhaps, sleep
disturbances.

6. THE ENDOCANNABINOID SYSTEM MODULATING THE SLEEP-WAKE CYCLE

Significant achievements have been obtained by describ-
ing the modulatory role of the endocannabinoid system in
the sleep-wake cycle. Pharmacological evidence from ex-
periments on central or peripheral administrations has
shown that elements of the endocannabinoid family parti-
cipate in sleep control. For example, pioneer studies by the
laboratory of Gerard Le Fur [111], Vincent Santucci, and
coworkers demonstrated that the systemic injections of the
CB1 cannabinoid receptor antagonist SR 141716A (0.1, 0.3,
1, 3 and 10 mg/Kg) increased the time spent in wakefulness
(W) while decreased slow-wave sleep (SWS) and REMs
whereas opposite results were described by our group in
1998 after icv injection of anandamide [112]. Remarkably,
the sleep-inducing effects of anandamide were blocked by
SR141716A [113].

Another element of the endocannabinoid system involved
in sleep modulation includes the FAAH. This assumption is
supported by studies in which administrations either icv or
into the lateral hypothalamus of URB597, a relatively selec-
tive inhibitor of FAAH, enhanced W and decreased SWS
during the lights-on period [114, 115]. Previous findings
have indicated that injections of URB597 enhance waking
and decrease sleep. An unexpected result since one might
think that inhibition of FAAH should increase anandamide
contents and then, facilitates sleep onset. However, data sug-
gest that the effects on sleep caused by UR597 might be due
to the accumulation of oleoylethanolamide (OEA) and/or
palmitoylethanolamide (PEA) since FAAH also synthesizes
both lipids in greater amounts compared to anandamide. In
line with this idea, our group demonstrated that the adminis-
tration of OEA or PEA increases wakefulness and reduces
SWS and REM sleep mimicking URB597’s effects [114,
115]. Lastly, OEA behaves as an agonist with high-affinity
for the PPAR-α [116], raising the possibility that PPAR-α
could be the mechanism of action of OEA to induce waking
[117, 118]. Further studies have also shown that additional
system are engaged in the pharmacological effects on sleep
of URB597, OEA or PEA, including the dopaminergic neu-
rotransmission [114, 115, 117, 118].

In another set of experiments in which rats received
AMT inhibitors, VDM-11 or OMDM-2, REMS was in-
creased [119, 120]. This data suggested that REMs promo-
tion could be as a consequence of the enhancement in the
endogenous contents of anandamide.

To elucidate the role of the CB1 cannabinoid receptor,
FAAH and AMT in sleep homeostasis, experimental animals
were subjected to total sleep deprivation and they received
before the sleep rebound period, systemic injection of either
SR141716A, UR8597, or VDM-11 (5, 10, 20mg/Kg; ip; sepa-
ately each one). As expected, SR141716A and UR8597
blocked the sleep rebound whereas VDM-11 exerted oppo-
site effects [121].

Finally, what might be the role of the endocannabinoid
system in sleep medicine? The fact that anandamide has been
associated with sleep apnea [86, 122-124] points to the pos-
sibility that the CB1 cannabinoid receptor, FAAH, MAGL, or
AMT may also be related to sleep disorders and they could
act as criteria for diagnostic sleep disturbances.

Thus, the information available allows us to identify the
elements of the endocannabinoid family as candidates for
sleep control. Nevertheless, there is a lack of data demo-
strating whether the endocannabinoid system may control
sleep disorders in aging since most of the current data has
been mostly reported in young or adult animals.

7. DOES THE ENDOCANNABINOID SYSTEM MODULATE SLEEP DISORDERS IN THE ELDERLY?

There is a significant amount of experimental and pre-
clinical evidence demonstrating that the endocannabinoid
system is linked with neurobiological processes related to
aging. For example, murine models lacking the CB1 cannabi-
noid receptors display an early onset of learning disturbances
linked with aging. These findings have contributed to the
design of drugs aimed to manage age-related human path-
ologies via the endocannabinoid system elements, such as
the CB1 cannabinoid receptors, anandamide, FAAH, AMT,
amongst others [124-132]. We would like to describe a hy-
pothetical framework regarding the likely modulatory role of
the endocannabinoid system on sleep disorders in the elderly
(Fig. 1).

7.1. The CB1 Cannabinoid Receptor

Anandamide and 2-AG promote sleep via activation of
the CB1 cannabinoid receptor [92, 112, 113]. The available
literature has indicated that the CB1 cannabinoid receptor in
aged rats seems to be decreased [125, 133].

7.2. The Endogenous Tone of Anandamide or 2-AG

Diurnal variation of endocannabinoids has been detected
in cerebrospinal fluid, pons, hippocampus, or hypothalamus
in rats [134, 135]. For example, anandamide in CSF showed
an enhancement during the lights-on period whereas de-
creased across the lights-off period in young rats whereas
anandamide and 2-AG levels are decreased in aging [126,
136, 137].
7.3. FAAH and MAGL

It is widely accepted that anandamide is synthesized on demand and regulated by the activity of FAAH whereas 2-AG is predominantly hydrolyzed to arachidonic acid and glycerol by MAGL [138]. Thus, the activity of these enzymes in the regulation of anandamide and 2-AG contents is critical. In this regard, Pascual et al., (2014) demonstrated that FAAH activity was decreased in the frontal cortex from patients with Alzheimer's disease [139] whereas the similar findings were reported for MAGL in Alzheimer's disease experimental murine models [140-142]. In line with this data, Piyanova et al., (2015) found an elevated MAGL activity during aging [143].

7.4. AMT

As mentioned previously, the AMT behaves as a carrier-mediated transport for anandamide across the neuronal membrane. Unfortunately, limited data are available regarding the role of AMT in aging. To our understanding, the only research that has covered this issue comes from Maccarrone et al., (2001) who reported that mice lacking the CB1 cannabinoid receptor showed a significant increase in AMT with age, whereas minor changes were found in wild-type animals [142].

Since aging is characterized by the progressive impairment of diverse physiological functions leading to developing medical disturbances, including neurodegenerative dis-
eases, then the study of the likely interaction of the endocannabinoid system with the mechanisms linked to age-related disturbances represents an interesting route for testing novel therapeutics. Here, we propose a conceptual framework linking the endocannabinoid system and the control of sleep disturbances in aging. However, our hypothetical proposal requires further evaluation by, for example, describing the distribution in the central nervous system of the CB1 cannabinoid receptor in aging and how they are altered under specific sleep disorders. Second, further evidence is required to address the modulation of the endocannabinoid system using experimental models of sleep disturbances targeting cannabinoid receptors with agonists or antagonists, increasing anandamide and 2-AG endogenous tone by the inhibition of FAAH or MAGL activity as well as the functioning of AMT. Lastly, translational studies should provide perspectives on how to bridge from basic science to human health for the developing endocannabinoid-based diagnostics and therapies for sleep disturbances in aging.

8. CANNABINOIDS SEEM TO BE PROMISING BUT WAIT! WHAT ABOUT THE LONG-TERM EFFECTS IN THE ELDERLY DUE TO THE STIMULATION BY CANNABINOIDS DURING CHILDHOOD?

Δ9-THC and cannabidiol (CBD) are the major chemicals in Cannabis sativa. While the first compound has been related to neurobiological disturbances, the second one does not exert psychotropic effects. Thanks to the research during the decades of the 1980s and 1990s, it was possible the characterization of the membrane binding sites for Δ9-THC. Currently, it is accepted that exogenous and endogenous cannabinoids bind to the CB1 and CB2 cannabinoid receptors [68, 69, 71, 72]. Due to the description of the cannabinoid receptors in human organs, including the central nervous system, the localization of these receptors correlated the behavioral effects and the administration of Δ9-THC [144-147].

Due to CBD not inducing undesirable effects, it has been considered as a promising compound in the last decades. In line with this, CBD seems to manage several medical conditions such as psychosis, inflammation, asthma, autism, and pediatric epilepsy [148]. In recent years, it has been suggested the clinical application of CBD for managing anxiety and sleep disturbances such as posttraumatic stress disorder [149-153]. Thus, as one can suspect, the accelerating acceptance of CBD-based products aimed for treating several illnesses should raise questions whether long-uses of CBD could induce adverse effects in aging.

The importance of discussing the putative long-term effects of CBD on sleep in aging lies in the evidence that shows the interaction among this compound and some elements of the endocannabinoid system. For example, current approaches have suggested that CBD behaves as a CB1 cannabinoid receptor negative allosteric modulator [154-157]. Moreover, CBD inhibits FAAH activity and modulates anandamide and 2-AG levels [158]. Thus, it seems reasonable to suspect that long-term exposure to CBD during early years might induce sleep disturbances in aging.

To increase awareness in regards to putative effects derived from long-term uses of CBD, various reports have demonstrated that this phytocannabinoid engages multiple neurobiological systems [148], including the increase of the extracellular contents of acetylcholine, adenosine, dopamine, and serotonin [159-161]. Since it has not been described which of these neurobiological pathways could be responsible for the presumably therapeutic properties of CBD, then...
multiple neurobiological routes might be engaged in the long-term prescription of this compound. Due to CBD tested exerting positive outcomes in epilepsy [162-165], then this phytocannabinoid has been also evaluated as a therapeutic option for managing schizophrenia, Alzheimer disease, autism, among others pathological conditions [148-150]. Therefore, the chronic use of CBD might cause undesirable effects in aging. To sum concerns, on-line availability and accessibility to CBD to products which do not fulfill FDA standards [166], could add healthy risks due to the chronic use of CBD. If used at juvenile ages, the neuronal development might be under the influence of CBD since the brain networks are still actively developing during adolescence [167]. Hence, the long-term use of CBD might induce neurobiological dysfunctions if treatment extends from childhood to adulthood as previously suggested (Fig. 2 [168-171]).

9. THE LIMITATIONS OF CURRENT EVIDENCE

At this date, the evidence of long-term disturbances in aging by lasting uses of CBD across childhood is limited and restricts to draw solid conclusions. We have identified that limitations of available literature include the variability of the experimental designs used animal model/clinical condition (epilepsy, anxiety, depression, etc.), dosage (e.g., low vs. high), route of administration (central vs. peripheral), frequency of usage (chronic vs. acute), among other conditions [145, 148, 172]. Moreover, achieving longitudinal studies that show time-varying exposure related to neurobiological effects in chronically CBD-treated subjects will provide experimental evidence to translate to medical areas where uses of CBD seems to be common such as pediatric epilepsy.

CONCLUSIONS

The increase in the number of aged people around the world and age-related health disturbances is a worldwide challenge. To note, the costs of dementia in the USA was more than US$800 billion in 2015, corresponding to a 35% increase compared to 2010 [1-6]. Thus, aging phenomena should promote the development of new therapeutical approaches.

During aging, the sleep-wake cycle includes abnormalities classified as sleep disorders, such as insomnia, obstructive sleep apnea, and excessive somnolence, among many others. Since projective models have indicated that the number of the oldest population would be higher, then this situation will also represent a public health challenge to assist age-related health issues, including sleep disorders. Here, we integrated the current knowledge of some sleep disorders in aging. The endocannabinoid system and its relationship with aging were revised as well. Lastly, the hypothetical link between the endocannabinoid system and sleep disorders in aging were proposed.

Moving our analysis from the endocannabinoid system and the neuronal circuits engaged on the sleep-wake cycle regulation is beyond the aim of the current Review since further complexity has been recognized by the localization of the elements of the endocannabinoid system in multiple sleep-related brain areas as well as the neuronal networks that underlie the influence of the endocannabinoid system in sleep control. Since the CB1 cannabinoid receptor, anandamide, 2-AG, and FAAH have been identified in sleep brain areas such as the cerebral cortex, hypothalamus and pons [173, 174], then we can assume that the endocannabinoid system might modulate the sleep-wake cycle. However, clinical implications between the endocannabinoid system functioning and sleep disturbances in aging require further investigation. Moreover, future research should focus on identifying the mechanisms of action of the multiple elements of the endocannabinoid system in aging and sleep disturbances as well as the risks of neurobiological durable effects in aging if the chronic prescription of CBD is provided across childhood.

Given the medical regulations in several countries allowing the medicinal uses of Cannabis sativa or compounds derived of cannabinoids, and the on-line accessibility to CBD, a diversity of uncontrolled and available CBD-containing products (e.g. oils, foods, drinks, gums, etc.) on the internet, which some of them do not meet the rigorous FDA standards [168] would increase the influx of subjects with acute illnesses searching purported medicinal products that could cause additional concerns than resolution of these. Thus, legitimate concerns are raised about the risks of neurobiological durable effects in adulthood if CBD is prescribed during juvenile ages. Moreover, there is no solid evidence in regards to each Cannabis sativa ingredient, or its mixture could exert positive outcomes for treating sleep disorders.

Although a plethora of pharmacological evidence of the endocannabinoid system have recently been suggested relevant for its likely sleep-modulatory properties in aging, the possibility that some beneficial outcomes for age-related sleep disturbances regulation could be achieved by indirect mechanism such as the control of pain, anxiety, depression, among other medical conditions [175-177] remains to be unclear at present.

CONSENT FOR PUBLICATION

Not applicable.

FUNDING

This work was supported by The University of California Institute for Mexico and the United States (UC MEXUS) and Consejo Nacional de Ciencia y Tecnología (CONACyT; Grant CN-17-19) and Escuela de Medicina, Universidad Anáhuac Mayab (Grant: PresInEMR2017) given to E M-R.

CONFLICT OF INTEREST

The authors declare no conflict of interest, financial or otherwise.

ACKNOWLEDGEMENTS

All authors contributed substantially to the article.

REFERENCES

[1] World Health Organization. Global Health and Aging. National Institute on Aging National Institutes of Health U.S. Department of Health and Human Services. USA. NIH. Publication no. 11-7737. 2011.
The Endocannabinoid System May Modulate Sleep Disorders in Aging

Beard, J.R.; Officer, A.; de Carvalho, I.A.; Sadana, R.; Pot, A.M.; Michel, J.P.; Lloyd-Sherlock, P.; Epping-Jordan, J.E.; Peeters, G.M.E.E.G.; Mahanani, W.R.; Thiyagarajan, J.A.; Chatterji, S. The World report on ageing and health: a policy framework for healthy ageing. *Lancet*, 2016, 387(10033), 2145-2154. [PMID: 26520231]

Gömkör, F.; Cafaro, P.; O’Sullivan, J. Aging human populations: good for us, good for the earth. *Trends Ecol. Evol. (Amst)*, 2018, 33(11), 851-862. [PMID: 30340868]

Ferrucci, L.; Giallauria, F.; Guralnik, J.M. Epidemiology of aging. *Radiol. Clin. North Am.* 2008, 46(4), 643-652. [PMID: 18922285]

Rohde, J.E. Far more than 7 billion. *Lancet Infect. Dis.* 2012, 12(1), 12. [PMID: 22192129]

Beard, J.R.; Officer, A.; de Carvalho, I.A.; Sadana, R.; Pot, A.M.; Michel, J.P.; Lloyd-Sherlock, P.; Epping-Jordan, J.E.; Peeters, G.M.E.E.G.; Mahanani, W.R.; Thiyagarajan, J.A.; Chatterji, S. The World report on ageing and health: a policy framework for healthy ageing. *Lancet*, 2016, 387(10033), 2145-2154. [PMID: 26520231]

Tugwell, P.; Knottnerus, J.A. Multimorbidity and Comorbidity are now separate MESH headings. *J. Clin. Epidemiol.*, 2019, 105, vii-xxii. [PMID: 30522770]

Mayo, S. Commonly used approach for multimorbidity frailty and multimorbidity: a systematic review and meta-analysis. *J. Gerontol. A Biol. Sci. Med. Sci.*, 2019, 74(5), 659-666. [PMID: 31076806]

Tisminetzky, M.; Gurtwiz, J.H.; Fan, D.; Reynolds, K.; Smith, D.H.; Magid, D.J.; Sung, S.H.; Murphy, T.E.; Goldberg, R.J.; Go, A.S. Multimorbidity burden and adverse outcomes in a community-based cohort of adults with heart failure. *J. Am. Geriatr. Soc.*, 2018, 66(12), 2305-2313. [PMID: 30246862]

Calderón-Larrághaga, A.; Fratiglioni, L. Multimorbidity research at the crossroads: developing the scientific evidence for clinical practice and health policy. *J. Intern. Med.* 2019, 285(3), 251-254. [PMID: 30625511]

Nicholson, K.; Makovski, T.T.; Griffith, L.E.; Raina, P.; Stranges, S.; van den Akker, M. Multimorbidity and comorbidity revisited: refining the concepts for international health research. *J. Clin. Epidemiol.*, 2019, 105, 142-146. [PMID: 30325315]

Childs, B.G.; Durik, M.; Baker, D.J.; van Deuren, J.M. Cellar encesence in aging and age-related disease: from mechanisms to therapy. *Nat. Med.*, 2015, 21(12), 1424-1435. [PMID: 26646499]

Fung, C.H.; Vitiello, M.V.; Alessi, C.A.; Kuchel, G.A. AGS/NIA sleep sleep planning Committee and faculty. Report and research agenda of the American geriatrics society and national institute on aging bedside-to-bench conference on sleep, Circadian rhythms, and aging: New avenues for improving brain health, physical health, and functioning. *J. Am. Geriatr. Soc.*, 2016, 64(12), e238-e247. [PMID: 27858974]

Mander, B.A.; Winer, J.R.; Walker, M.P. Sleep and human aging. *Neuron*, 2017, 94(1), 19-36. [PMID: 28159095]

Miner, B.; Kryger, M.H. Sleep in the aging population. *Sleep Med. Clin.*, 2017, 12(1), 31-38. [PMID: 28159095]

Messer, E.S.; Bhamasani, M.; Zangrelli, M.A.; Morris, J.C.; Holtzman, D.M.; Ju, Y.S. Circadian rest-activity pattern changes in aging and preclinical Alzheimer disease. *JAMA Neurol.*, 2018, 75(3), 582-590. [PMID: 29379963]

Dong, X.; Milholland, B.; Vijg, J. Evidence for a limit to human lifespan. *Nature*, 2016, 538(7624), 257-259. [PMID: 27070136]
Skoog, I.; Kivipelto, M. Sleep disturbances and dementia risk: A multicenter study. *Alzheimers Dement.*, 2018, 14(10), 1235-1242. [http://dx.doi.org/10.1016/j.jalz.2018.05.012] [PMID: 30030112]

Demauviorès, J.; Desjardins, S.; Lapierre, S.; Desgagné, A. Sleep environment and insomnia in elderly persons living at home. *J. Aging Res.*, 2018, 2018, 8053696. [http://dx.doi.org/10.1155/2018/8053696] [PMID: 30363712]

Abad, V.C.; Guilleminault, C. Insomnia in elderly patients: Recommendations for pharmacological management. *Drugs Aging.*, 2018, 35(9), 791-817. [http://dx.doi.org/10.1007/s40266-018-0569-8] [PMID: 30058034]

Brandão, G.S.; Camelier, F.W.R.; Sampaio, A.A.C.; Brandão, G.S.; Silva, A.S.; Gomes, G.S.B.F.; Donner, C.F.; Oliveira, L.V.F.; Camelier, A.A. Association of sleep quality with excessive daytime somnolence and quality of life of elders of community. *Multidis. Cip. Respir. Med.*, 2018, 13, 8.

[http://dx.doi.org/10.1186/s40864-018-0120-0] [PMID: 29568522]

Garbarino, S.; Scoditti, E.; Lanteri, P.; Conte, L.; Magnavita, N.; Toraldo, D.M. Obstructive sleep apnea with or without excessive daytime sleepiness: Clinical and experimental data-driven phenomena. *Front. Neurol.*, 2018, 9, 505. [http://dx.doi.org/10.3389/fneur.2018.00505] [PMID: 29997573]

Kim, J.W.; Kim, T.; Shin, J.; Choe, G.; Lim, H.J.; Rhee, C.S.; Lee, K.; Cho, S.W. Prediction of obstructive sleep apnea based on respiratory sounds recorded between sleep onset and sleep offset. *Clin. Exp. Otorhinolaryngol.*, 2019, 12(1), 72-78. [http://dx.doi.org/10.1016/j.cej.2018.03.038] [PMID: 30189718]

Carneiro-Barrera, A.; Díaz-Román, A.; Guillén-Riquelme, A.; Buela-Casal, G. Weight loss and lifestyle interventions for obstructive sleep apnoea in adults: Systematic review and meta-analysis. *Obes. Rev.*, 2019, 20(5), 750-762. [http://dx.doi.org/10.1111/obr.12824] [PMID: 30609450]

[http://dx.doi.org/10.1111/obr.12824]

[http://dx.doi.org/10.1016/j.sleep.2017.03.015] [PMID: 28778240]

Junho, B.T.; Kummer, A.; Cardoso, F.; Teixeira, A.L.; Roche, N.P. Clinical predictors of excessive daytime sleepiness in patients with Parkinson’s disease. *J. Clin. Neurol.*, 2018, 14(4), 530-536. [http://dx.doi.org/10.3988/jcn.2018.14.4.530] [PMID: 30198233]

Maugeri, A.; Medina-Inojosa, J.R.; Kunzova, S.; Agodi, A.; Barcìtta, M.; Sochor, O.; Topinková, E.; Šonka, K. Narcolepsy with cataplexy in patients aged over 60 years: a case-control study. *Sleep Med.*, 2016, 26, 79-84. [http://dx.doi.org/10.1016/j.sleep.2016.05.011] [PMID: 27665501]

Gabelle, A.; Jaussent, I.; Hirtz, C.; Vialaret, J.; Navucet, S.; Grasset, C.; Robert, P.; Lehmann, S.; Dauvilliers, Y. Cerebrospinal fluid levels of orexin-A and histamine, and sleep profile within the Alzheimer process. *Neurobiol. Aging.*, 2017, 53, 59-66. [http://dx.doi.org/10.1016/j.neurobiolaging.2017.01.011] [PMID: 28325679]

Suzuki, K.; Miyamoto, M.; Hira, K. Sleep disorders in the elderly: Diagnosis and management. *J. Gen. Fam. Med.*, 2017, 18(2), 61-71. [http://dx.doi.org/10.1007/s12679-017-0300-z] [PMID: 29226399]

Salas-Crisostomo, M.; Torterolo, P.; Veras, A.B.; Roche, N.B.; Machado, S.; Murillo-Rodríguez, E. Therapeutic approaches for the management of sleep disorders in geriatric population. *Curr. Med. Chem.*, 2019, 26(25), 4775-4785. [http://dx.doi.org/10.2174/09298673566180901115115] [PMID: 30182852]

Augustin, S.M.; Lofving, D.M. Functional relevance of endocannabinoid-dependent synaptic plasticity in the central nervous system. *ACS Chem. Neurosci.*, 2018, 9(9), 2146-2161. [http://dx.doi.org/10.1021/acschemneuro.7b00508] [PMID: 29400439]

Ayermer, M.S.; Asa, E.; Abellanas, M.A.; Tolon, R.M.; Ramos, J.A.; Ferrer, I.; Romero, J.; Fernández-Moreno, J.; Aymerich, M.S.; Aso, E.; Abellanas, M.A.; Tolon, R.M.; Ramos, J.A. Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system. *Biochem. Pharmacol.*, 2018, 157, 67-84. [http://dx.doi.org/10.1016/j.bcp.2018.08.016] [PMID: 30121249]

Ibarra-Lecue, I.; Pilar-Cuellar, F.; Maguruz, C.; Florensa-Zanuy, E.; Díaz, A.; Urgüen, L.; Castro, E.; Pazos, A.; Callado, L.F. The endocannabinoid system in mental disorders: Evidence from human brain studies. *Biochim. Pharmacol.*, 2018, 157, 97-107. [http://dx.doi.org/10.1016/j.bcp.2018.07.009] [PMID: 30026022]

Jordan, C.; Xí, X.Z. Progress in brain cannabinoid CB2 receptor research: From genes to behavior. *Neurosci. Biobehav. Rev.*, 2019, 99, 2146-2161. [http://dx.doi.org/10.1016/j.neubiorev.2019.05.017] [PMID: 31977634]

Hombali, A.; Seow, E.; Yuan, Q.; Chang, S.H.S.; Satghare, P.; Kumar, S.; Verma, S.K.; Mok, Y.M.; Chong, S.A.; Subramaniam, M. Prevalence and correlates of sleep disorder symptoms in psychiatric inpatients. *Psychiatry Res.*, 2018, S0165-1714(18), 30268-3. [http://dx.doi.org/10.1016/j.psychres.2018.07.009] [PMID: 30072039]

K, Pavlova, M.; Latreille, V. Sleep disorders. *Am. J. Med.*, 2018, pii: S0002-9343(18)30094-4.

[http://dx.doi.org/10.1016/j.amjmed.2018.06.007]

Gulia, K.K.; Kumar, V.M. Sleep disorders in the elderly: a growing challenge. *Psychogeriatrics*, 2018, 18(3), 155-165. [http://dx.doi.org/10.1111/pogy.12319] [PMID: 29878472]

Iranzo, A. Parasomnia and sleep-related movement disorders in older adults. *Sleep Med. Clin.*, 2018, 13(1), 51-61. [http://dx.doi.org/10.1016/j.smlc.2017.09.005] [PMID: 29412983]

Miner, B.; Kryger, M.H. Sleep in the aging population. *Sleep Med. Clin.*, 2017, 12(1), 31-38. [http://dx.doi.org/10.1016/j.smlc.2016.10.008] [PMID: 28159095]

Grandner, M.A.; Winkelman, J.W. Nocturnal leg cramps: Prevalence and associations with demographics, sleep disturbance symptoms, medical conditions, and cardiometabolic risk factors. *Plos One.*, 2017, 12(6), e0178465. [http://dx.doi.org/10.1371/journal.pone.0178465] [PMID: 28586374]

Yaremchuk, K. Sleep disorders in the elderly. *Clin. Geriatr. Med.*, 2018, 34(2), 205-216. [http://dx.doi.org/10.1016/j.cger.2018.01.008] [PMID: 29661333]

Wang, C.; Wang, Q.; Ji, B.; Pan, Y.; Xu, C.; Cheng, B.; Bai, B.; Chen, J. The orexin/Orexin Receptor system: Molecular mechanism and therapeutic potential for neurological diseases. *Front. Mol. Neurosci.*, 2018, 11, 220. [http://dx.doi.org/10.3389/fnmol.2018.00220] [PMID: 30002617]
The Endocannabinoid System May Modulate Sleep Disorders in Aging

The emerging role of the endocannabinoid system in the sleep-wake cycle modulation. *Cent. Nerv. Syst. Agents Med. Chem.*, 2011, 11(3), 189-196.

[88] Engeli, S.; Blüher, M.; Jumpertz, R.; Wiesner, T.; Wirtz, H.; Bosse-Henck, A.; Stumvoll, M.; Batkai, S.; Pacher, P.; Harvey-White, J.; Kunos, G. Jordan, J. Circulating anandamide and blood pressure in patients with obstructive sleep apnea. *J. Hypertens.*, 2012, 30(12), 2345-2351. [PMID: 23032139]

[89] Murillo-Rodríguez, E.; Palomero-Rivero, M.; Millán-Albacar, D.; Di Marzo, V. The administration of endocannabinoid uptake inhibitors OMDM2 or OMDM1 promotes sleep and decreases extracellular levels of dopamine in rats. *Physiol. Behav.*, 2013, 109, 88-95. [PMID: 23228348]

[90] Murillo-Rodríguez, E.; Machado, S.; Rocha, N.B.; Budde, H.; Yuan, T.F.; Arias-Carrion, O. Revealing the role of the endocannabinoid system modulators, SR141716A, URB597 and VDM-11, in sleep homeostasis. *Neuroscience*, 2016, 339, 433-449. [PMID: 27746343]

[91] Hanlon, E.C.; Taselli, E.; Leproutil, R.; Stuhrl, K.; Doncheck, E.; de Wit, H.; Hillard, C.J.; Van Cauter, E. Sleep restriction enhances nocturnal endocannabinoids in the BRN. *Sleep Res.*, 2017, 46, 146-145. [PMID: 28161591]

[92] Chanda, D.; Neumann, D.; Glatz, J.F.C. The endocannabinoid system: Overview of an emerging multi-faced therapeutic target. *Prostaglandins Leukot. Essent. Fatty Acids*, 2019, 149, 51-56. [PMID: 30353044]

[93] Maccarrone, M. Metabolism of the endocannabinoid anandamide: open questions after 25 years. *Front. Mol. Neurosci.*, 2017, 10, 166. [PMID: 28380166]

[94] Naziroglu, M.; Taner, A.N.; Balbay, E.; Çığ, B. Inhibitions of anandamide transport and FAAH synthesis decrease apoptosis and oxidative stress through inhibition of TRPV1 channel in an in vitro seizure model. *Cell. Biochem. Biol.*, 2019, 453-(1,2), 143-155. [PMID: 30159798]

[95] Storozhuk, M.V.; Zholos, A.V. TRP Channels as Novel Targets for Sleep. *Front. Physiol.*, 2016, 9(2345), 653-664. [PMID: 26612385]

[96] Cazares, O.; Anandamide and 2-arachidonoylglycerol. *J. Neurosci.*, 2018, 39, 189-204. [PMID: 30262909]

[97] Choi, S.H.; Arai, A.L.; Mou, Y.; Kang, B.; Yen, C.C.; Hallenbeck, J.M. Transcriptional regulation of endocannabinoid in postmortem brain of schizophrenic subjects. *Schizophr. Res.*, 2013, 1481, 3-15, 145-150. [PMID: 23800614]

[98] Rodríguez-Cueto, C.; Hernández-Galváñez, M.; Hillard, C.J.; Maciel, P.; Valdeolivias, S.; Ramos, J.A.; Gómez-Ruiz, M.; Fernández-Ruiz, J. Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3. *PLoS One*, 2017, 12(4), e0176521. [PMID: 28448548]

[99] Micalle, V.; Drago, F. Endocannabinoid system, stress and HPA axis. *Eur. J. Pharmacol.*, 2018, 834, 230-239. [PMID: 29962888]

[100] Aso, E.; Andreau, D.; Ferrer, I. Genetic deletion of CB1 cannabinoid receptors exacerbates the Alzheimer-like symptoms in a transgenic animal model. *Biochem. Pharmacol.*, 2018, 157, 210-216. [PMID: 29962888]

[101] Choi, S.H.; Ariai, A.L.; Mou, Y.; Kang, B.; Yen; C.C.; Hallenbeck, J. Silva; A.C. Neuroprotective effects of MAG1 (Monocayglycerol Lipase) inhibition in experimental ischemic stroke. *Stroke*, 2018, 49(3), 718-726. [PMID: 29110616]
Basilavizzi, D.; Arias-Murillo, A.; Leza, J.C.; Bernardo, M. FLAMM Endocannabinoid system in neurodegenerative disorders. J. Alzheimers Dis., 2015, 48(1), 33-41.

[PMID: 25944765] [PMID: 27146668] [PMID: 27786440]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, M.T.; Caraza-Martínez, R.; Gómez, A. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Marchado, S.; Ibañez, M.; Moreno, M.; Zúñiga, C.; Tolón, R.M.; Grande, M.T.; Caraza-Martínez, R.; Gómez, A. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]

Murillo-Rodríguez, M.; Zúñiga, C.; Tolón, R.M.; Grande, A.; Gómez, A.; Ibañez, M.; Caraza-Martínez, R.; Moreno, M. The endocannabinoid system in psychiatric disorders. Mol. Psychiatry, 2017, 22(8), 1638-1661.

[PMID: 28485025] [PMID: 28606881] [PMID: 28790967]
against age-related bone loss by osteoclast inhibition. *Aging Cell*, 2017, 16(5), 1051-1061.

[130] Cassano, T.; Calcagnini, S.; Pace, L.; De Marco, F.; Romano, A.; Gaetani, S. Cannabinoid receptor 2 signaling in neurodegenerative Disorders: From pathogenesis to a promising therapeutic target. *Front. Neurosci.*, 2017, 11, 30.

[131] Bilikei-Gorzo, A.; Albayram, O.; Drahfehn, A.; Michel, K.; Piya- nova, A.; Oppenheimer, H.; Dvir-Ginzberg, M.; Racz, I.; Ulas, T.; Imbeaut, S.; Bab, I.; Schultz, J.L.; Zimmer, A. A chronic low dose of Δ2-tetrahydrocannabinol (THC) restores cognitive function in old mice. *Nat. Med.*, 2017, 23(6), 782-787.

[132] Canseco-Alba, A.; Schanz, N.; Sanabria, B.; Zhao, J.; Lin, Z.; Liu, Q.R.; Onaivi, E.S. Behavioral effects of psychostimulants in mutan mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons. *Behav. Brain Res.*, 2019, 366, 286-297.

[133] Berrendero, F.; Romero, J.; García-Gil, L.; Suarez, I.; De la Cruz, P.; Ramos, J.A.; Fernández-Ruiz, J.J. Changes in cannabinoid receptor binding and mRNA levels in several brain regions of aged rats. *Biochim. Biophys. Acta*, 1998, 1407(3), 205-214.

[134] Valenti, M.; Viganò, D.; Casico, M.G.; Rubino, T.; Steardo, L.; Parolaro, D.; Di Marzo, V. Differential diurnal variations of anandamide and 2-arachidonoyl-glycerol levels in rat brain. *Cell. Mol. Life Sci.*, 2004, 61(7-8), 945-950.

[135] Murillo-Rodríguez, E.; Desarnaud, F.; Prospéro-Garcia, O. Diurnal variation of arachidonoylanethanolamine, palmitoylethanolamide and oleoylthanolamide in the brain of the rat. *Life Sci.*, 2006, 79(1), 30-37.

[136] Maroof, N.; Ravigati, S.; Pardon, M.C.; Barrett, D.A.; Kendall, D.A. Reductions in endocannabinoid levels and enhanced coupling of cannabinoid receptors in the striatum are accompanied by cognitive impairments in the APPSwe/PS1ΔE9 mouse model of Alzheimer’s disease. *J. Alzheimer’s Dis.*, 2014, 42(1), 227-245.

[137] Schaich, C.L.; Shaltout, H.A.; Graubner, M.; Thomas, B.F.; Gallagher, P.E.; Howlett, A.C.; Diz, D.I. Alterations in the medullary endocannabinoid system contribute to age-related impairment of baroreflex sensitivity. *J. Cardiovasc. Pharmacol.*, 2015, 65(5), 473-479.

[138] Tsu, W.; Lelu-Chavain, N.; Spencer, J.; Sansook, S.; Millet, R.; Chavatte, P. Therapeutic potential of fatty acid amide hydrolase, monoacylglycerol lipase, and N-acylethanolamine acid amidase Inhibitors. *J. Med. Chem.*, 2017, 60(1), 4-46.

[139] Pascual, A.C.; Martin-Moreno, A.M.; Giusto, N.M.; de Ceballos, M.L.; Pasquéar, S.J. Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: modulation by cannabinoid agonists. *Exp. Gerontol.*, 2014, 60, 92-99.

[140] Pascual, A.C.; Gaviglio, V.L.; Giusto, N.M.; Pasquéar, S.J. Aging modifies the enzymatic activities involved in 2-arachidonoylglycerol metabolism. *Biofactors*, 2013, 39(2), 209-220. [http://dx.doi.org/10.1002/biof.1055] [PMID: 23281018]

[141] Pascual, A.C.; Gaviglio, V.L.; Giusto, N.M.; Pasquéar, S.J. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. *Exp. Gerontol.*, 2014, 55, 134-142.

[142] Maccarrone, M.; Attinà, M.; Bari, M.; Cartoni, A.; Ledent, C.; Finazzi-Agro, A. Anandamide degradation and N-acyl ethanolamines level in wild-type and CB1 cannabinoid receptor knockout mice of different ages. *J. Neurochem.*, 2001, 78(2), 339-348. [http://dx.doi.org/10.1046/j.1471-4159.2001.00413.x] [PMID: 11461969]

[143] Piyanova, A.; Lomazzo, E.; Bindila, L.; Lerner, R.; Albayram, O.; Ruhl, T.; Lutz, B.; Zimmer, A.; Bilikei-Gorzo, A. Age-related changes in the endocannabinoid system in the mouse hippocampus. *Mech. Ageing Dev.*, 2015, 150, 55-64. [http://dx.doi.org/10.1016/j.mad.2015.08.005] [PMID: 26278494]

[144] Lu, H.C.; Mackie, K. An Introduction to the endogenous cannabinoid system. *Biol. Psychiatry*, 2016, 79(7), 516-525. [http://dx.doi.org/10.1016/j.biopsych.2015.09.031] [PMID: 26698193]

[145] Ruhl, E.B. Cannabinoids therapies and the future of neurology. *Front. Integr. Neurosci.*, 2017, 12, 51. [http://dx.doi.org/10.3389/fnint.2018.00051] [PMID: 30405366]

[146] Schrot, R.J.; Hubbard, J.R. Cannabinoids: Medical implications. *Ann. Med.*, 2016, 48(3), 128-141. [http://dx.doi.org/10.1016/j.annmed.2015.08.005] [PMID: 26912385]

[147] World Health Organization 2018. Cannabidiol(CBD) Critical Review Report. https://www.who.int/medicines/access/controlled substances/CannabidiolCriticalReview.pdf

[148] Ibas Bih, C.; Chen, T.; Nunn, A.V.; Bazelot, M.; Dallas, M.; Whalley, B.J. Molecular targets of cannabinoid in neurological Disorders. *Neurotherapeutics*, 2015, 12(4), 699-730. [http://dx.doi.org/10.1007/s13311-015-0377-3] [PMID: 26264914]

[149] National Academies of Sciences, engineering, and medicine. 2017. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. Washington, DC: The National Academies Press.[http://dx.doi.org/10.17226/24625]

[150] Charles, M.H.; Eckeli, A.L.; Zuaidi, A.W.; Pena-Pereira, M.A.; Sobreira-Neto, M.A.; Sobreira, E.T.; Camilo, M.R.; Bergamaschi, M.M.; Schenck, C.H.; Hallak, J.E.; Tumas, V.; Crippa, J.A. Cannabinoids can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. *J. Clin. Pharm. Ther.*, 2014, 39(5), 564-566. [http://dx.doi.org/10.1111/jcpt.12179] [PMID: 24845114]

[151] Shannon, S.; Opila-Lehman, J. Effectiveness of cannabidiol oil for pediatric anxiety and insomina as part of posttraumatic stress disorder: A case report. *Perm. J.*, 2016, 20(4), 16-005. [http://dx.doi.org/10.7812/tpipp-16-005] [PMID: 27768570]

[152] Shannon, S.; Lewis, N.; Lee, H.; Hughes, S. Cannabidiol in anxiety and sleep: A large case series. *Perm. J.*, 2019, 23, 18-041. [http://dx.doi.org/10.7812/tpipp-18-041] [PMID: 30621494]

[153] Pertwee, R.G. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabinvarin. *Br. J. Pharmacol.*, 2008, 153(2), 199-215. [http://dx.doi.org/10.1038/bj.2007.442] [PMID: 17828291]

[154] Navarro, G.; Reyes-Santisteban, R.; Sánchez de Medina, V.; Morales, P.; Casano, S.; Ferreiro-Vera, C.; Lillo, A.; Aguinaga, D.; Jagerovic, N.; Nadal, X.; Franco, R. Cannabidiol skews biased agonism at cannabinoid CB1 and CB2 receptors with smaller effect in CB2-CB: heteroreceptor complexes. *Biochem. Pharmacol.*, 2018, 157, 148-158.

[155] Fogaça, M.V.; Campos, A.C.; Coelho, L.D.; Duman, R.S.; Gui- marães, F.S. The anxiolytic effects of cannabinoid in chronically stressed mice are mediated by the endocannabinoid system: Role of neurogenesis and dendritic remodeling. *Neuropharmacology*, 2018, 135, 22-33. [http://dx.doi.org/10.1016/j.neuropharm.2018.03.001] [PMID: 29510816]

[156] Mijangos-Moreno, S.; Poot-Aké, A.; Aranowsky-Sandoval, G.; Murillo-Rodríguez, E. Intrahyphal injection of cannabidiol...
increases the extracellular levels of adenosine in nucleus accumbens in rats. *Neurosci. Res.*, 2014, 84, 60-63. [http://dx.doi.org/10.1016/j.neures.2014.04.006] [PMID: 24800644]

[160] Murillo-Rodriguez, E.; Di Marzo, V.; Machado, S.; Rocha, N.B.; Veras, A.B.; Neto, G.A.M.; Budde, H.; Arias-Carrion, O.; Aranowsky-Sandoval, G. Role of N-arachidonoyl-serotonin (AA-5T1T) in sleep-wake cycle architecture, sleep homeostasis, and neurotransmitters Regulation. *Front. Mol. Neurosci.*, 2017, 10, 152. [http://dx.doi.org/10.3389/fnmol.2017.00152] [PMID: 28611585]

[161] Murillo-Rodriguez, E.; Aranowsky-Sandoval, G.; Rocha, N.B.; Peniche-Amante, R.; Veras, A.B.; Machado, S.; Budde, H. Systemic injections of cannabidiol enhance acetylcholine levels from basal forebrain in rats. *Neurochem. Res.*, 2018, 43(8), 1511-1518. [http://dx.doi.org/10.1007/s11064-018-2565-0] [PMID: 29876791]

[162] Slomski, A. Fewer seizures with cannabidiol in vatastrophic Epilepsy. *JAMA*, 2017, 318(4), 323. [http://dx.doi.org/10.1001/jama.2017.8846] [PMID: 28742905]

[163] Devinsky, O.; Patel, A.D.; Cross, J.H.; Villanueva, V.; Wirrell, E.C.; Privitera, M.; Greenwood, S.M.; Roberts, C.; Checketts, D.; VanLandingham, K.E.; Zuberi, S.M. GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-gastaut Syndrome. *N. Engl. J. Med.*, 2018, 378(20), 1888-1897. [http://dx.doi.org/10.1056/NEJMoa1714631] [PMID: 29768152]

[164] Rubin, R. The path to the first FDA-approved cannabis-derived treatment and what comes next. *JAMA*, 2018, 320(12), 1227-1229. [http://dx.doi.org/10.1001/jama.2018.11914] [PMID: 30193588]

[165] Ebbert, J.O.; Scharf, E.L.; Hurt, R.T. Medical cannabis. *Mayo Clin. Proc.*, 2018, 93(1), 1842-1847. [http://dx.doi.org/10.1016/j.mayocp.2018.09.005] [PMID: 30522595]

[166] Freedman, D.A.; Patel, A.D. Inadequate regulation contributes to mislabeled online cannabidiol products. *Pediatr. Neurol. Briefs*, 2018, 32, 3. [http://dx.doi.org/10.10584/penneurol-briefs.32-3] [PMID: 3008541]

[167] Keshavan, M.S.; Giedd, J.; Lau, J.Y.; Lewis, D.A.; Paus, T. Changes in the adolescent brain and the pathophysiology of psychotic disorders. *Lancet Psychiatry*, 2014, 1(7), 549-558. [http://dx.doi.org/10.1016/S2215-0366(14)00081-9] [PMID: 26361314]

[168] Luján, M.A.; Castro-Zavala, A.; Alegré-Zurano, L.; Valverde, O. repeated cannabidiol treatment reduces cocaine intake and modulates neural proliferation and CB1R expression in the mouse hippocampus. *Neuropharmacology*, 2018, 143, 163-175. [http://dx.doi.org/10.1016/j.neuropharm.2018.09.043] [PMID: 30273593]

[169] Schiavon, A.P.; Bonato, J.M.; Milani, H.; Guimarães, F.S.; Welfort de Oliveira, R.M. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. *Prog. Neuropsychopharmacol. Biol. Psychiatry*, 2016, 64, 27-34. [http://dx.doi.org/10.1016/j.pnpbp.2015.08.017] [PMID: 26187374]

[170] Carvalho, R.K.; Souza, M.R.; Santos, M.L.; Guimarães, F.S.; Pobbe, R.L.H.; Andersen, M.L.; Mazaro-Costa, R. Chronic cannabidiol exposure promotes functional impairment in sexual behavior and fertility of male mice. *Reprod. Toxicol.*, 2018, 81, 34-40. [http://dx.doi.org/10.1016/j.reprotox.2018.06.013] [PMID: 29936126]

[171] Ilfand, K.; Grottenhemen, F. An Update on safety and side effects of cannabidiol: A review of clinical data and relevant animal studies. *Cannabis Cannabinoid Res.*, 2017, 2(1), 139-154. [http://dx.doi.org/10.1089/can.2016.0034] [PMID: 28861514]

[172] Sands, T.T.; Rahdari, S.; Oldham, M.S.; Caminha, N.E.; Tilton, N.; Cilio, M.R. Long-Term Safety, Tolerability, and Efficacy of cannabidiol in children with refractory Epilepsy: Results from an expanded access program in the US. *CNS Drugs*, 2019, 33(1), 47-60. [http://dx.doi.org/10.1007/s40263-018-0589-2] [PMID: 30460546]

[173] Deutsch, D.G.; Ueda, N.; Yamamoto, S. The fatty acid amide hydrolase (FAAH). *Prostaglandins Leukot. Essent. Fatty Acids*, 2002, 66(2-3), 201-210. [http://dx.doi.org/10.1054/plef.2001.0358] [PMID: 12052036]

[174] Hu, S.S.; Mackie, K. Distribution of the endocannabinoid system in the central nervous system. *Handb. Exp. Pharmacol.*, 2015, 231, 59-93. [http://dx.doi.org/10.1007/978-3-219-20825-1_3] [PMID: 26408158]

[175] Shin, M.; Ware, T.B.; Lee, H.C.; Hsu, K.L. Lipid-metabolizing serine hydrolases in the mammalian central nervous system: endocannabinoids and beyond. *Biochem. Biophys. Acta Mol. Cell Biol. Lipids*, 2019, 1866(4), 907-921. [http://dx.doi.org/10.1016/j.bbalaip.2018.08.007] [PMID: 30905349]

[176] Donvito, G.; Nass, S.R.; Wilkerson, J.L.; Curry, Z.A.; Schurman, L.D.; Kinsey, S.G.; Lichtman, A.H. The endogenous cannabinoid system: A budding source of targets for treating inflammatory and neuropathic Pain. *Neuropsychopharmacology*, 2018, 43(1), 52-79. [http://dx.doi.org/10.1002/npp.20720] [PMID: 28857069]

[177] Stampanoni Bassi, M.; Gilio, L.; Maffei, P.; Dolcetti, E.; Bruno, A.; Buttari, F.; Centonze, D.; Iezzi, E. Exploiting the multifaceted effects of cannabinoids on mood to boost their therapeutic Use Against Anxiety and Depression. *Front. Mol. Neurosci.*, 2018, 11, 424. [http://dx.doi.org/10.3389/fnmol.2018.00424] [PMID: 30515077]